Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–67 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Nephrotic Syndromes Clear all

Conditions: Sphingolipidoses, Enzyme Deficiency
Interventions: no intervention; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions: frexalimab, brivekimig, rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 15 more

Conditions: Glomerulonephritis, Nephrotic Syndrome
Interventions: Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nephrotic Syndrome
Interventions: Acthar Gel and Tacrolimus; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions: D-Galactose; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions: GFB-887, Placebo; Drug
Lead sponsor: Goldfinch Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more

Conditions: Edema, Hypervolemia, Chronic Kidney Diseases, Nephrotic Syndrome
Interventions: Diuretic Tuner; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nephrotic Syndrome in Children
Interventions: Corticosteroids; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 1 Year to 18 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: Transcutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer, Diabetes, Metabolic Associated Steatotic Liver Disease
Interventions: High carb then high fat breakfast, High fat then high carb breakfast; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nephrotic Syndrome
Interventions: Implementation of a gluten-free diet; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 9 Months to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Nephrotic Syndrome
Interventions: Prednisolone; Drug
Lead sponsor: All India Institute of Medical Sciences; Other
Eligibility: 1 Year to 4 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Stanford, California • Ann Arbor, Michigan + 1 more

Conditions: Idiopathic Nephrotic Syndrome
Interventions: Standard of Care, UrApp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon

Conditions: Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: VB119; Drug
Lead sponsor: Tenet Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Albany, New York

Conditions: Crohn's Disease, Nephrotic Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years to 21 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Nephrotic Syndrome, Systemic Lupus Erythematosus
Interventions: prednisone, cyclophosphamide, cyclosporin A; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1986 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Focal Segmental Glomerulosclerosis
Interventions: CCX140-B; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more

Conditions: Glomerular Disease
Interventions: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more

Conditions: Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions: Pirfenidone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Diuretic Tuner Clinical Decision Support

Steroid Sensitive Nephrotic Syndrome in Children

taVNS for FRNS in Children

Effects of Meal Macronutrients on Postprandial Lipids

Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker

Prednisolone Trial in Children Younger Than 4 Years

UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Glucocorticoid-induced Osteopenia in Children

Drug Therapy in Lupus Nephropathy

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Vitamin D Supplementation in Glomerular Disease

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)